AstraZeneca's ETCAMAH (camizestrant) receives US FDA accelerated approval for metastatic breast cancer

AstraZeneca announced that its drug ETCAMAH (camizestrant) received US FDA accelerated approval for HR-positive HER2-negative metastatic breast cancer with ESR1 mutations, as disclosed in a SEC filing. The company also reported a positive result in a separate lung disease drug trial.

Detected & updated continuously · Source: Nebula